中华骨科杂志
中華骨科雜誌
중화골과잡지
CHINESE JOURNAL OF ORTHOPAEDICS
2013年
5期
495-500
,共6页
黄迅悟%冯会成%孙继桐%常青%关长勇%余方圆%彭伟%包二平
黃迅悟%馮會成%孫繼桐%常青%關長勇%餘方圓%彭偉%包二平
황신오%풍회성%손계동%상청%관장용%여방원%팽위%포이평
髋关节%结核,骨关节%关节成形术,置换,髋
髖關節%結覈,骨關節%關節成形術,置換,髖
관관절%결핵,골관절%관절성형술,치환,관
Hip joint%Tuberculosis,osteoarticular%Arthroplasty,replacement,hip
目的 探讨活动性髋关节结核一期病灶清除全髋关节置换的可行性及其临床疗效.方法 回顾性分析2007年1月至2010年10月期间接受一期病灶清除全髋关节置换治疗的28例晚期活动性髋关节结核患者的相关资料,男17例,女11例;年龄18~72岁,平均36岁.8例单纯关节内脓肿,20例合并关节周围脓肿;均有髋臼及股骨头骨破坏.术前红细胞沉降率为28~102 mm/1 h,平均52 mm/1 h;C反应蛋白为11~73 mg/L,平均38 mg/L.9例合并肺结核,1例合并脊柱结核,术前抗结核治疗时间平均7周(3~32周).所有患者术中均彻底清除髋关节周围脓肿、髋臼死骨,将切除的股骨头颈清除病灶组织后置于体积分数75%酒精浸泡5 min,用生理盐水冲洗,用于骨缺损区植骨,采用非骨水泥型假体置换.病理检查证实为髋关节结核.术后系统抗结核治疗18个月.结果 28例患者均获得随访,随访时间24~56个月,平均37个月.所有患者切口一期愈合,红细胞沉降率恢复正常时间平均为3.3个月(2~5个月),C反应蛋白恢复正常时间平均为2.1个月(1~3个月).髋关节Harris评分从(30.214±9.350)分改善至(90.535±6.746)分.1例患者术后13个月自行停用抗结核化疗后结核复发,术后56个月随访时患者能行走,股骨柄和髋臼杯无松动,目前保留假体密切随访中.结论 活动性全髋关节结核在有效抗结核化疗的基础上行一期病灶清除全髋关节置换可获得较好的临床疗效.
目的 探討活動性髖關節結覈一期病竈清除全髖關節置換的可行性及其臨床療效.方法 迴顧性分析2007年1月至2010年10月期間接受一期病竈清除全髖關節置換治療的28例晚期活動性髖關節結覈患者的相關資料,男17例,女11例;年齡18~72歲,平均36歲.8例單純關節內膿腫,20例閤併關節週圍膿腫;均有髖臼及股骨頭骨破壞.術前紅細胞沉降率為28~102 mm/1 h,平均52 mm/1 h;C反應蛋白為11~73 mg/L,平均38 mg/L.9例閤併肺結覈,1例閤併脊柱結覈,術前抗結覈治療時間平均7週(3~32週).所有患者術中均徹底清除髖關節週圍膿腫、髖臼死骨,將切除的股骨頭頸清除病竈組織後置于體積分數75%酒精浸泡5 min,用生理鹽水遲洗,用于骨缺損區植骨,採用非骨水泥型假體置換.病理檢查證實為髖關節結覈.術後繫統抗結覈治療18箇月.結果 28例患者均穫得隨訪,隨訪時間24~56箇月,平均37箇月.所有患者切口一期愈閤,紅細胞沉降率恢複正常時間平均為3.3箇月(2~5箇月),C反應蛋白恢複正常時間平均為2.1箇月(1~3箇月).髖關節Harris評分從(30.214±9.350)分改善至(90.535±6.746)分.1例患者術後13箇月自行停用抗結覈化療後結覈複髮,術後56箇月隨訪時患者能行走,股骨柄和髖臼杯無鬆動,目前保留假體密切隨訪中.結論 活動性全髖關節結覈在有效抗結覈化療的基礎上行一期病竈清除全髖關節置換可穫得較好的臨床療效.
목적 탐토활동성관관절결핵일기병조청제전관관절치환적가행성급기림상료효.방법 회고성분석2007년1월지2010년10월기간접수일기병조청제전관관절치환치료적28례만기활동성관관절결핵환자적상관자료,남17례,녀11례;년령18~72세,평균36세.8례단순관절내농종,20례합병관절주위농종;균유관구급고골두골파배.술전홍세포침강솔위28~102 mm/1 h,평균52 mm/1 h;C반응단백위11~73 mg/L,평균38 mg/L.9례합병폐결핵,1례합병척주결핵,술전항결핵치료시간평균7주(3~32주).소유환자술중균철저청제관관절주위농종、관구사골,장절제적고골두경청제병조조직후치우체적분수75%주정침포5 min,용생리염수충세,용우골결손구식골,채용비골수니형가체치환.병리검사증실위관관절결핵.술후계통항결핵치료18개월.결과 28례환자균획득수방,수방시간24~56개월,평균37개월.소유환자절구일기유합,홍세포침강솔회복정상시간평균위3.3개월(2~5개월),C반응단백회복정상시간평균위2.1개월(1~3개월).관관절Harris평분종(30.214±9.350)분개선지(90.535±6.746)분.1례환자술후13개월자행정용항결핵화료후결핵복발,술후56개월수방시환자능행주,고골병화관구배무송동,목전보류가체밀절수방중.결론 활동성전관관절결핵재유효항결핵화료적기출상행일기병조청제전관관절치환가획득교호적림상료효.
Objective To evaluate the feasibility and clinical efficacy of one-stage focal debridement and total hip replacement (THR) in treatment of active tuberculosis of the hip.Methods A retrospective analysis was done for 28 cases of active hip tuberculosis who were treated with one-stage focal debridement and THR in our hospital from January 2007 to October 2010.There were 17 males and 11 females,with an average age of 36 years (range,18-72 years).Eight patients had abscess only inside the joint,while 20 also had periarticular abscess.All patients had acetabular and femoral head damage.The erythrocyte sedimentation rate (ESR) before operation averaged 52 mm/l h (range,28-102 mm/lh),and the C-reactive protein (CRP) averaged 38 mg/L (range,11 to 73 mg/L).The anti-tuberculous treatment before operation lasted 7 weeks in average (range,3-32 weeks).The abscess and acetabular sequestra around the joint were cleared in all operations.The removed femoral head and neck issue were cleared from focus,soaked in 75% alcohol for 5 min,washed with saline,and used as implant in area of bone defect.Cementless THR was performed.All cases were confirmed as hip tuberculosis by pathological examination.Anti-tuberculous treatment was applied for 18 months after operation.Results All of 28 patients were followed up for an average of 37 months (range,24-56 months).All patients had first intention healing.ESR returned to normal in an average of 3.3 months (range,2-5 months),and CRP 2.1 months (range,1-3 months).The Harris hip score improved from 30.214±9.350 preoperatively to 90.535±6.746 postoperatively.One patient stopped anti-tuberculosis chemotherapy 13 months after operation at his own choice,and relapsed.He was able to walk 56 months after operation,and no loosening was observed in the hip stem or acetabular cup.The patient has the prosthesis retained and is under close follow-up.Conclusion It is reliable to use one-stage focal debridement and THR based on effective anti-tuberculous chemotherapy to treat active tuberculosis of the hip.